Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor.

Drug metabolism and disposition: the biological fate of chemicals - 1 May 2026

Vourvahis Manoli, Orozco Christine C, Tess David, Zhang Yizhong, Bauman Jonathan N, Gosset James R, Amin Neeta B, Cerny Matthew A

Abstract excerpt

Ervogastat (PF-06865571) is a potent and selective small-molecule inhibitor of diacylglycerol-O-acyltransferase-2 currently in clinical development for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis. A fixed sequence 2-period 14C-microtracer crossover study was used to determine a comprehensive and quantitative overview of the total disposition of ervogastat after oral and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Biological Availability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Diacylglycerol O-Acyltransferase

Share to Enzyme Inhibitors

Share to Pyridines

Share to Tissue Distribution

Source

Identifiers

PMID: 42061200
DOI: 10.1016/j.dmd.2026.100286

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor.PMID 42061200Read ↗

Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.Semantic proximity Read ↗

Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites.Semantic proximity Read ↗

A UPLC-MS based exploration of the xenobiotic and endogenous metabolic phenotypes of pre-clinical models of hepatotoxicitySemantic proximity Read ↗

Cytochrome P450 reaction phenotyping: State of the art.Semantic proximity Read ↗

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.Semantic proximity Read ↗

PharmGKB summary: venlafaxine pathway.Semantic proximity Read ↗

Amelioration of the Pharmacokinetics and Tissue Distribution of Flurbiprofen Axetil by Glycyrrhetinic Acid Derivatives for Enhanced Safety and EfficacySemantic proximity Read ↗

Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers.Semantic proximity Read ↗

Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.Semantic proximity Read ↗

Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes.Semantic proximity Read ↗

Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing EnzymesSemantic proximity Read ↗

Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.